Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Barriers that remain in the treatment of pediatric ALL with CAR-T therapies

Christina Peters • 15 Apr 2024
EBMT 2024
Acute Lymphoblastic Leukemia Leukemia CAR-T

Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, addresses ongoing challenges in CAR-T therapy for pediatric acute lymphoblastic leukemia (ALL). CAR-T is approved only for relapsed/refractory (R/R) cases, where T-cells are frequently exhausted from prior treatments like chemotherapy or allogeneic stem cell transplantation (alloSCT). Furthermore, post-CAR-T relapses often necessitate subsequent alloSCT. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Christina Peters

1:57
TBI prior to alloSCT in patients with ALL: the FORUM trials
Christina Peters • 15 Apr 2024
2:14
Optimizing bridging therapy for CAR-T in children and young adults with R/R ALL
Christina Peters • 15 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:05
FORUM results: TBI vs myeloablative chemo-based conditioning pre-alloSCT in high-risk pediatric ALL
Christina Peters • 23 Apr 2023

Related Videos

2:05
CAR T-cell therapy programs to improve access for patients with leukemia in Mexico
Alberto Olaya-Vargas • 15 Apr 2024
14:43
Current research into post-alloSCT maintenance therapy in AML
Ali Bazarbachi • 3 May 2024
5:20
Targeted therapies in AML: menin, FLT3 and IDH inhibitors
Felicitas Thol • 19 Apr 2024
4:15
Using MRD to guide post-alloSCT treatment decisions in AML
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals